- Home/
- China/
- World Health Organisation/
- Overview
World Health Organisation Tender
World Health Organisation Tender
Costs
EMD
NA
Summary
Agreement For Performance Of Work (apw) Hiv, Hepatitis And Sti (hsi) Open New Window
Description
Background As Part Of China’s Commitment To Achieving The Sustainable Development Goals (sdgs), The "healthy China 2030" Plan Provides The Framework For Implementing Health. Viral Hepatitis Elimination As A Public Health Threat By 2030 Is Part Of Achieving Target 3.3 Of The Sdgs. To Further Strengthen The Prevention And Control Of Viral Hepatitis In China, The National Health Commission (nhc) Released The Strategic "china Viral Hepatitis Prevention And Treatment Plan (2017-2020)" In 2017. In The Last Several Years, There Have Been Major Evolution Towards Hepatitis Elimination In China In Terms Of New Guidelines, Policies And Dramatic Prices Reductions For Hepatitis B And C Medicines In The Country. Prices Of Hepatitis B Medicines Reduced By 300-fold And For Direct Acting Antivirals (daas) This Was An 85% Reduction To A Threshold Which Enable The Drugs To Be Included Under The National Drug Reimbursement List. However, Challenges Continue In Reporting Towards The Who Global Hepatitis Reporting For The Continuum Of Care Cascade For Testing, Diagnosis, And Treatment. There Is Lack Of Clear Mechanisms To Synthesise The Various Data Needed To Report On The Cascade Of Care, Especially For Treatment. It Is Unclear The Range Of Sources Of Data To Get Estimations Of Diagnostic And Treatment Numbers. Due To The Complexity Of Health Systems In China, There Is Need To Understand How The Data Sources Are Structured E.g. Insurance Database And/or Other Sources Of Information For Treatment Numbers, Either At National And/or At Provincial Level. As Well There Is Rapid Ongoing Reforms By The National Health Insurance Agency On Its Information Systems At All Levels. It Is Currently Unclear If The Policy And Drug Price Reductions Have Resulted In Increased Uptake Of Treatment For Hepatitis B And C (i.e. The Policy-implementation Gap) And If There Are Other Factors Which May Influence Expansion Of Access And Uptake E.g. Benefit Package, Price Negotiations, Pooled Procurement, Enablers For The Hospital Systems To Make Commodities More Accessible And Available, Etc.. In Order To Support The Country In Strengthening The Strategic Information And Response Strategy, An Understanding Of The Data Sources For Cascade Numbers, In Particular Treatment Data, Is Needed To Support The Work Of Who In Facilitating The Country’s Path To Hepatitis Elimination. As Well, It Would Be Important To Understand The Policy Impact - Implementation Barriers/gaps So That Solutions May Be Designed. Purpose And Description Of Activities To Be Carried Out The Hiv, Hepatitis And Sti Team (hsi) At Wpro Is Seeking Technical Expertise To Support Designing And Implementing A Study To Generate Data/information On People With Chronic Hepatitis B And C, In Particular, Treatment Estimates At National And Subnational Level, As Well As Policy Related Factors Influencing The Treatment Uptake In China. The Findings And Evidence Generated By This Study Are Expected To Contribute To The Formulation Of The Who Strategy And Actions On How To Better Support National Response To Viral Hepatitis In China. Description Of Activities To Be Carried Out The Successful Contractor Shall, In Collaboration With Who Regional Office And China Office, Perform The Activities Essential And Needed For Achieving The Project Objectives, Including But Not Limited To The Following: Develop A Plan And Describe Possible Data Sources On Estimation Of Treatment, Describe Appropriate Approaches To Generate And Use Data/information On The Estimated Number Of People Living With Hepatitis B And C Who Receive Antiviral Treatment, And Policy Related Factors Influencing Treatment Uptake In China. Specific Details Include: To Map And Describe The Possible Data Sources Which Can Report Estimations Of Treatment, As A Proxy Of Access To Treatment, I.e. Numbers Receiving Hbv And Hcv Treatment, And To Establish The Approach On Analysis And Understand The Structure, Details, Content Of The Different Database To See How To Apply This For Public Health Evidence Generation; To Gain Understanding Of The Associated Factors And Key Barriers Of Antiviral Treatment Of Hepatitis B And C Based On Qualitative Analyses; To Conduct Quantitative Estimations Of The Antiviral Treatment Of Hepatitis B And C At National And Regional Levels Based On Data Collected From The Best Possible Data Source(s); To Make Assessments Of The Impacts On The Antiviral Treatment Of Major Antiviral Medication Policies, Including The Essential Medicines List Coverage, Health Insurance Coverage And Novel Payment Mechanism, Price Negotiation And Pooled Procurement, As Well As Other Health And Health Insurance Administration And Regulations; And Develop And Submit Technical Report Of The Study. Methods To Carry Out The Activity And List Of Outputs The Contractor Is Expected To Provide The Methods For The Study. In View Of The Impact Of Covid-19 In China, Flexibility Is Expected For Travel Locally To Province If Data Collection Is To Be Done Sub-nationally. The Contractor Is Expected To Work Virtually Otherwise, Liaising Closely With The Who China Country Office Focal Point For Hepatitis As Well As The Technical Unit At The Who Office For The Western Pacific. Where Travel Is Needed For Local/sub-nationally Data Collections, This Should Be Included In The Budget For The Study. Output 1: develop A Plan Which Includes Description Of Possible Data Sources On Estimation Of Treatment, Describe Appropriate Approaches To Generate And Use Data/information On The Estimated Number Of People Living The Hepatitis B And C Who Receive Antiviral Treatment, And Policy Related Factors Influencing Treatment Uptake In China. Deliverable 1.1: Draft Plan To Map And Describe The Possible Data Sources Which Can Report Estimations Of Treatment, As A Proxy Of Access To Treatment, I.e. Numbers Receiving Hbv And Hcv Treatment, And To Establish The Approach On Analysis And Understand The Structure, Details, Content Of The Different Database To See How To Apply This For Public Health Evidence Generation. Deliverable 1.2: Draft Analysis Plan For The Conduct Of The Quantitative Estimations Of The Antiviral Treatment Of Hepatitis B And C At National And Regional Levels Based On Data Collected From The Best Possible Data Source(s). Deliverable 1.3: Draft Plan For Stakeholder Discussions To Understand Policy Impacts And Barriers For Antiviral Treatment Uptake. Output 2: Submission Of Draft Technical Report, Presentation And Manuscript Deliverable 2.1: Draft Technical Report At The Close Of 2021 With Key Information On Methods Used, Main Activities Conducted, Main Findings Covering The Topics Of The Study Listed Above, And Policy Recommendations For Planning, Implementation And Promotion Of Hepatitis Treatment In China. Deliverable 2.2: Presentation On The Near-final Reports At A Seminar With Invited Relevant Stakeholders By The End Of 2021. Deliverable 2.3: Report And A Briefing Report Ready For Sharing With The Government. The English Publishable Manuscript Drafted Based On The Study To A Peer Review International Journal Within 3 Months After The Study Is Expected, Working In Collaboration With Who. Qualifications & Experience Education Essential: Contractor(s) Should Be An Institution With The Required Public Health Expertise To Implement The Project, Or who Can Manage This Project In China. Locally Based Contractor(s) Are Encouraged As The Project Is Expected To Include Daily Work In Mandarin. Experience Essential: The Contractor(s) Should Have Experience Working In Public Health With Proven Expertise In Designing And Implementing Studies On Treatment Access And Influencing Factors For The Diseases With Major Public Health Significance, And In Data Collection, Analysis, Generation And Use Of Strategic Information For Policy Advocacy. The Contractor Should Have Thorough Understanding Of The Situation Of Viral Hepatitis Epidemic And Response In China, Have The Ability And Network To Mobilize Resources Essential For Success Of The Proposed Study Such As Easy Access To Data At National And Subnational Level And Previous Studies/researches, Competent Researchers, Communication Skills And Technologies, And Etc. The Contractor Should Be Able To Engage With Key Stakeholders And Soliciting The Views Of Stakeholders In Different Disciplines, And The Successful Bidder Should Have Ability To Meet Deadlines With Quality Products. Desirable: Experience Of Working In Public Health Policy, Access To Medicines, Intellectual Property And Pharmaceutical Polices Areas Within Asia. Documented Experience In Policy Mapping, Analysis And Development Of Recommendations On Practical Solutions. Previous Work With Who Or United Nations Agencies. Languages Expert Level Of Mandarin And English Is Essential (read-write-speak). Competencies Teamwork Respecting And Promoting Individual And Cultural Differences Communication Moving Forward In A Changing Environment Additional Information: Place Of Assignment Virtual Work In General. Depending On The Study Methods And Covid-19 Travel Restrictions, Local Travel In China May Be Needed For Data Collection. Duration Of Contract 4 Months Starting 7 September 2021 Medical Clearance Not Applicable Travel Depending On The Study Methods And Covid-19 Travel Restrictions, Local Travel In China May Be Needed For Data Collection. Proposal Format Bidders Must Submit A Portfolio, With Budgets, And The Cvs Of The Lead Experts In Order To Clearly Articulate Their Capacity And Skill, As Well As The Technical Proficiency. The Successful Contractor Shall Provide In The Proposal Bid The Following: 1. Design And Methods Of The Study 2. Potential Data Sources Of Treatment Numbers At National And Subnational Or Other Relevant Policy Impacts May Be Estimated 3. Possible Methods For Estimations Of Treatment Numbers For Hbv And Hcv 4. Methods For Policy Impact Analysis Documenting Changes In Treatment Access Due To Policy Shifts 5. Proposed Timeline For Each Activity 6. Financial Proposal (in Usd), And According To The Requirement Provided In The Terms Of Reference Applications Qualified And Interested Specialists Should Submit The Following Documents To The Supply Officer Through Wp Ro Ungm At < Wproungm@who.int > By 27 August 2021 (17:00 Gmt+8 Manila) • Curriculum Vitae (for Individual Contractors) Or Company Profile (for Institutional Applications) • Expression Of Interest (cover Letter). The Cover Letter Should Outline How Their Experience And Qualifications Make Them A Suitable Candidate For This Position And Should Include Their Proposed Daily Fee And Availability. • Technical And Financial Proposals • Portfolio Please Use Tender Notice No. 138784 As Subject To All Submission. Only Successful Candidates Will Be Contacted.
Contact
Tender Id
138784Bid Award Id
ViewTender No
WPRO/2021-08/DDC_HSI/138784Tender Authority
World Health Organisation ViewPurchaser Address
-Website
https://www.who.int/